Sign In  |  Register  |  About Corte Madera  |  Contact Us

Corte Madera, CA
September 01, 2020 10:27am
7-Day Forecast | Traffic
  • Search Hotels in Corte Madera

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

Week in Review: Everest Announces Two In-Licensings with Total Value of $1 Billion

Deals and Financings   Shanghai Everest Medicines in-licensed a BTK inhibitor for renal diseases from Suzhou Sinovent and SinoMab Bio in a $561 million agreement; Everest also announced a $500 million deal for a mRNA COVID-19 vaccine and two other mRNA producs from Canada 's Providence Therapeutics; Cue Health, a  San Diego  company with China backers, filed for a $180 million US IPO to develop its home healthcare device, including a COVID-19 test; Haisco Pharma of Shannan in-licensed  China  rights to a novel osteoarthritis therapy from  San Diego 's Biosplice in a $140 million agreement; IASO, a  Nanjing  biopharma, completed a $108 million Series C round to advance its novel cell therapy and biologic products; Alebund Pharma, a  Shanghai  company focused on renal diseases, closed a $54.5 million Series B+ financing round; Florida 's Cytovia established a Shanghai JV with an initial $45 million to develop its off-the-shelf CAR products in  China ;  Trials and Approvals   Nanjing Legend Biotech was approved for a US Phase 1 trial of its autologous CD4 CAR-T lymphoma therapy; CStone Pharma of  Suzhou  will start  China  trials of its tri-specific immunotherapy, a next-gen anti-PD-1/PD-L1 that also targets 4-1BB and human serum albumin; Harbour BioMed was approved to start  China  trials of its next-gen CLTA-4/PD-1 candidate for hepatocellular and neuroendocrine carcinoma.  Stock Symbols: (HK 1952) (HK: 3681) (SHZ: 002653) (NSDQ: LEGN) (HK: 2616) (HK: 02142) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 CorteMadera.com & California Media Partners, LLC. All rights reserved.